Trial ID: | L6387 |
Source ID: | NCT02719756
|
Associated Drug: |
Metformin
|
Title: |
Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2
|
Acronym: |
|
Status: |
UNKNOWN
|
Study Results: |
NO
|
Results: |
|
Conditions: |
Diabetes Mellitus|Hypoglycemic Episodes
|
Interventions: |
DRUG: Metformin|DRUG: Dapagliflozin|DRUG: Metformin up-titration
|
Outcome Measures: |
Primary: Dynamics (delta from the baseline) of blood glucose variability - integral index of glycemia (LBGI-HBGI) after 3 months of therapy, 3 months | Secondary: Dynamics (delta from the baseline or % decrease of blood glucose level) of blood glucose variability (ADRR) after 3 months of therapy, 3 months|Dynamics of MAGE after 3 months of therapy, 3 months|Dynamic of glycaemia parameters: % of normoglycemia time after 3 months of therapy, 3 months|Dynamic of glycaemia parameters: % of hyperglycemia time after 3 months of therapy, 3 months|Dynamic of glycaemia parameters: % of hypoglycemia time after 3 months of therapy, 3 months|Dynamics of HbA1c (%) from baseline after 3 months of therapy, 3 months|Percentage of diabetes mellitus patients achieved individual target HbA1c, 3 months
|
Sponsor/Collaborators: |
Sponsor: Research Clinical Centre of the Russian Railways, JSC
|
Gender: |
ALL
|
Age: |
ADULT, OLDER_ADULT
|
Phases: |
PHASE4
|
Enrollment: |
100
|
Study Type: |
INTERVENTIONAL
|
Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose:
|
Start Date: |
2016-04
|
Completion Date: |
2016-12
|
Results First Posted: |
|
Last Update Posted: |
2016-03-25
|
Locations: |
Research Clinical Centre of the Russian Railways, JSC, Moscow, 125993, Russian Federation
|
URL: |
https://clinicaltrials.gov/show/NCT02719756
|